<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446847</url>
  </required_header>
  <id_info>
    <org_study_id>MCA-0867</org_study_id>
    <nct_id>NCT02446847</nct_id>
  </id_info>
  <brief_title>3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption</brief_title>
  <official_title>A Phase 2, Open Label Study of the Safety, Antiretroviral Activity and Pharmacokinetics of 3BNC117 During a Short Analytical Treatment Interruption in HIV-infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying
      rebound of viral load during a brief treatment interruption of standard ART and its safety
      during a brief analytical interruption of antiretroviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a Phase II, open label study to evaluate the safety and antiretroviral
      activity of two and four infusions of 3BNC117 in HIV-infected subjects on combination ART
      during a brief analytical treatment interruption.

      After meeting enrollment criteria sixteen subjects with 3BNC117 sensitive virus (&lt;2μg/ml
      IC50) will receive two (Group A) or four (Group B) intravenous infusions of 3BNC117,
      administered at 30 mg/kg.

      In both dosing groups, antiretroviral therapy will be discontinued 2 days after the first
      3BNC117 infusion (day 2) until week 12. Combination ART will be resumed at week 12. ART will
      be resumed sooner if plasma HIV-1 RNA level is ≥ 200 copies/ml or if CD4+ count drops &lt; 350
      cells/μl and either result is confirmed upon repeat measurement. Participants will be
      followed weekly until week 12 for safety assessments and for monitoring plasma HIV-1 RNA
      levels (viral load). CD4+ T cell counts will be monitored every 2 weeks until week 12.

      Participants may remain off antiretroviral therapy after week 12, with weekly viral load
      monitoring, if viral rebound does not occur by week 12. Participants will be followed for a
      total of 36 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2015</start_date>
  <completion_date type="Actual">March 25, 2017</completion_date>
  <primary_completion_date type="Actual">March 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Virologic Rebound at 8 Weeks After Interruption of Antiretroviral Therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Virologic rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Rate of Signs, Symptoms and Laboratory Abnormalities After 3BNC117 Infusions</measure>
    <time_frame>36 weeks</time_frame>
    <description>The percentage of participants who experienced adverse events (e.g. signs, symptoms and laboratory abnormalities) following 3BNC117 infusions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Plasma Level of 3BNC117 at the Time of Viral Rebound.</measure>
    <time_frame>36 weeks</time_frame>
    <description>The plasma concentrations of 3BNC117 at the time of viral rebound (i.e. confirmed plasma HIV-1 RNA levels &gt; 200 copies/ml).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Group A: 3BNC117 IV + ART Interruption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: 3BNC117 IV + ART interruption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3BNC117</intervention_name>
    <description>3BNC117 infusions</description>
    <arm_group_label>Group A: 3BNC117 IV + ART Interruption</arm_group_label>
    <arm_group_label>Group B: 3BNC117 IV + ART interruption</arm_group_label>
    <other_name>3BNC117 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ART Interruption</intervention_name>
    <description>Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
    <arm_group_label>Group A: 3BNC117 IV + ART Interruption</arm_group_label>
    <arm_group_label>Group B: 3BNC117 IV + ART interruption</arm_group_label>
    <other_name>Treatment Interruption</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65

          -  HIV-1 infection confirmed by ELISA and immunoblot.

          -  Plasma HIV-1 RNA &lt; 50 copies/ml for at least 12 months while on combination ART and &lt;
             20 copies/ml at the screening visit. [Note: One or two viral blips of &lt; 200 copies/mL
             prior to enrollment are permitted if preceded and followed by test results showing VL
             less than or equal to 50 copies/mL on the same ARV regimen.]

          -  3BNC117 sensitivity (IC50 &lt; 2 μg/ml) of subject derived HIV-1 virus isolates. These
             are isolated under protocol MCA-823 by co-culture of subject PBMCs with HIV-uninfected
             donor PBMCs followed by in vitro neutralization assays as previously described

          -  Current CD4 cell count &gt; 500 cells/μl and no prior CD4 cell count &lt; 200 cells/μl.

          -  Willing to interrupt antiretroviral treatment for 12 weeks, or until viral rebound
             occurs.

          -  If sexually active male or female, and participating in sexual activity that could
             lead to pregnancy using an effective method of contraception throughout the study
             period. Subjects should also agree to use a male or female condom during the time of
             pausing their HIV medication.

          -  If on an NNRTI-based regimen willing to a switch for 4 weeks to dolutegravir.

        Exclusion Criteria:

          -  Have a history of AIDS-defining illness within 1 year prior to enrollment

          -  History of systemic corticosteroids, immunosuppressive anti-cancer, or other
             medications considered significant by the trial physician within the last 6 months;

          -  Chronic hepatitis B or hepatitis C;

          -  Patient report, or chart history, of significant coronary artery disease, myocardial
             infarction, percutaneous coronary intervention with placement of cardiac stents;

          -  Patient report, or chart history, of diabetes type 1 or 2 and/or current use of
             insulin or oral hypoglycemic medications;

          -  Uncontrolled hypertension, as defined by a systolic blood pressure &gt; 180 and/or
             diastolic blood pressure &gt; 120, in the presence or absence of anti-hypertensive
             medications;

          -  Any other clinically significant acute or chronic medical condition, such as
             autoimmune diseases, that in the opinion of the investigator would preclude
             participation;

          -  Current cigarette use in excess of 1 pack per day;

          -  Laboratory abnormalities in the parameters listed below:

               -  Absolute neutrophil count ≤1,000

               -  Hemoglobin ≤ 10 gm/dL

               -  Platelet count ≤125,000

               -  ALT ≥ 2.0 x ULN

               -  AST ≥ 2.0 x ULN

               -  Total bilirubin ≥ 1.5 ULN

               -  Creatinine ≥ 1.1 x ULN

               -  Coagulation parameters ≥ 1.5 x ULN;

          -  Current antiretroviral regimen includes either maraviroc or enfuvirtide;

          -  Pregnancy or lactation;

          -  Any vaccination within 14 days prior to 3BNC117 administration;

          -  Receipt of any monoclonal antibody therapy of any kind in the past;

          -  Participation in another clinical study of an investigational product currently or
             within past 12 weeks, or expected participation during this study.

          -  History of resistance to two or more antiretroviral drug classes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Caskey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <results_first_submitted>June 3, 2020</results_first_submitted>
  <results_first_submitted_qc>July 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2020</results_first_posted>
  <disposition_first_submitted>April 13, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 19, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 24, 2018</disposition_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>3BNC117</keyword>
  <keyword>Broadly neutralizing antibody</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02446847/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02446847/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02446847/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A: 3BNC117 IV + ART Interruption</title>
          <description>Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
        </group>
        <group group_id="P2">
          <title>Group B: 3BNC117 IV + ART Interruption</title>
          <description>Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: 3BNC117 IV + ART Interruption</title>
          <description>Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
        </group>
        <group group_id="B2">
          <title>Group B: 3BNC117 IV + ART Interruption</title>
          <description>Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="26" upper_limit="62"/>
                    <measurement group_id="B2" value="38" lower_limit="27" upper_limit="59"/>
                    <measurement group_id="B3" value="42" lower_limit="26" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Virologic Rebound at 8 Weeks After Interruption of Antiretroviral Therapy</title>
        <description>Virologic rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: 3BNC117 IV + ART Interruption</title>
            <description>Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
          </group>
          <group group_id="O2">
            <title>Group B: 3BNC117 IV + ART Interruption</title>
            <description>Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virologic Rebound at 8 Weeks After Interruption of Antiretroviral Therapy</title>
          <description>Virologic rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Rate of Signs, Symptoms and Laboratory Abnormalities After 3BNC117 Infusions</title>
        <description>The percentage of participants who experienced adverse events (e.g. signs, symptoms and laboratory abnormalities) following 3BNC117 infusions.</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: 3BNC117 IV + ART Interruption</title>
            <description>Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
          </group>
          <group group_id="O2">
            <title>Group B: 3BNC117 IV + ART Interruption</title>
            <description>Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Signs, Symptoms and Laboratory Abnormalities After 3BNC117 Infusions</title>
          <description>The percentage of participants who experienced adverse events (e.g. signs, symptoms and laboratory abnormalities) following 3BNC117 infusions.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Plasma Level of 3BNC117 at the Time of Viral Rebound.</title>
        <description>The plasma concentrations of 3BNC117 at the time of viral rebound (i.e. confirmed plasma HIV-1 RNA levels &gt; 200 copies/ml).</description>
        <time_frame>36 weeks</time_frame>
        <population>Two participants excluded from analysis because of detectable plasma HIV-1 RNA levels prior to first administration of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 3BNC117 IV + ART Interruption</title>
            <description>Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
          </group>
          <group group_id="O2">
            <title>Group B: 3BNC117 IV + ART Interruption</title>
            <description>Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>The Plasma Level of 3BNC117 at the Time of Viral Rebound.</title>
          <description>The plasma concentrations of 3BNC117 at the time of viral rebound (i.e. confirmed plasma HIV-1 RNA levels &gt; 200 copies/ml).</description>
          <population>Two participants excluded from analysis because of detectable plasma HIV-1 RNA levels prior to first administration of the investigational product.</population>
          <units>micrograms/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.15" spread="42.41"/>
                    <measurement group_id="O2" value="74.37" spread="65.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for 36 weeks from enrollment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A: 3BNC117 IV + ART Interruption</title>
          <description>Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
        </group>
        <group group_id="E2">
          <title>Group B: 3BNC117 IV + ART Interruption</title>
          <description>Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
3BNC117: 3BNC117 infusions
ART Interruption: Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <description>The participant was admitted to the hospital with a transient ischemic attach 30 wks after last study intervention. The event was considered not related to the study, but secondary to underlying risk factors.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paresthesia upper extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marina Caskey, Associate Professor of Clinical Investigation</name_or_title>
      <organization>The Rockefeller University</organization>
      <phone>212-327-7396</phone>
      <email>mcaskey@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

